Evaluation of In Vitro Absorption, Distribution, Metabolism, and Excretion (ADME) Properties of Mitragynine, 7-Hydroxymitragynine, and Mitraphylline

 

 Buy Article Permissions and Reprints

Abstract

Mitragyna speciosa (kratom) is a popular herb in Southeast Asia, which is traditionally used to treat withdrawal symptoms associated with opiate addiction. Mitragynine, 7-hydroxymitragynine, and mitraphylline are reported to be the central nervous system active alkaloids which bind to the opiate receptors. Mitraphylline is also present in the bark of Uncaria tomentosa (catʼs claw). Several therapeutic properties have been reported for these compounds but limited information is available on the absorption and distribution properties. This study focuses on evaluating the absorption, distribution, metabolism, and excretion (ADME) properties of these compounds and their effect on major efflux transporter P-glycoprotein, using in vitro methods. Quantitative analysis was performed by the Q-TOF LC-MS system. Mitragynine was unstable in simulated gastric fluid with 26 % degradation but stable in simulated intestinal fluid. 7-Hydroxymitragynine degraded up to 27 % in simulated gastric fluid, which could account for its conversion to mitragynine (23 %), while only 6 % degradation was seen in simulated intestinal fluid. Mitraphylline was stable in simulated gastric fluid but unstable in simulated intestinal fluid (13.6 % degradation). Mitragynine and 7-hydroxymitragynine showed moderate permeability across Caco-2 and MDR-MDCK monolayers with no significant efflux. However, mitraphylline was subjected to efflux mediated by P-glycoprotein in both Caco-2 and MDR-MDCK monolayers. Mitragynine was found to be metabolically stable in both human liver microsomes and S9 fractions. In contrast, both 7-hydroxymitragynine and mitraphylline were metabolized by human liver microsomes with half-lives of 24 and 50 min, respectively. All three compounds exhibited high plasma protein binding (> 90 %) determined by equilibrium dialysis. Mitragynine and 7-hydroxymitragynine inhibited P-glycoprotein with EC₅₀ values of 18.2 ± 3.6 µM and 32.4 ± 1.9 µM, respectively, determined by the calcein-AM fluorescent assay, while no inhibition was seen with mitraphylline. These data indicate the possibility of a drug interaction if mitragynine and 7-hydroxymitragynine are coadministered with drugs that are P-glycoprotein substrates.

• References

• 1 Ulbricht C, Costa D, Dao J, Isaac R, LeBlanc YC, Rhoades J, Windsor RC. An evidence-based systematic review of kratom (Mitragyna speciosa) by the Natural Standard Research Collaboration. J Diet Suppl 2013; 10: 152-170
  CrossrefPubMedGoogle Scholar
• 2 Stolt AC, Schroder H, Neurath H, Grecksch G, Hollt V, Meyer MR, Maurer HH, Ziebolz N, Havemann-Reinecke U, Becker A. Behavioral and neurochemical characterization of kratom (Mitragyna speciosa) extract. Psychopharmacology (Berl) 2013; 231: 13-25
  PubMedGoogle Scholar
• 3 Hassan Z, Muzaimi M, Navaratnam V, Yusoff NH, Suhaimi FW, Vadivelu R, Vicknasingam BK, Amato D, von Horsten S, Ismail NI, Jayabalan N, Hazim AI, Mansor SM, Muller CP. From Kratom to mitragynine and its derivatives: physiological and behavioural effects related to use, abuse, and addiction. Neurosci Biobehav Rev 2013; 37: 138-151
  CrossrefPubMedGoogle Scholar
• 4 Leon F, Habib E, Adkins JE, Furr EB, McCurdy CR, Cutler SJ. Phytochemical characterization of the leaves of Mitragyna speciosa grown in USA. Nat Prod Commun 2009; 4: 907-910
  PubMedGoogle Scholar
• 5 Jamil MF, Subki MF, Lan TM, Majid MI, Adenan MI. The effect of mitragynine on cAMP formation and mRNA expression of mu-opioid receptors mediated by chronic morphine treatment in SK-N-SH neuroblastoma cell. J Ethnopharmacol 2013; 148: 135-143
  CrossrefPubMedGoogle Scholar
• 6 Utar Z, Majid MI, Adenan MI, Jamil MF, Lan TM. Mitragynine inhibits the COX-2 mRNA expression and prostaglandin E(2) production induced by lipopolysaccharide in RAW264.7 macrophage cells. J Ethnopharmacol 2011; 136: 75-82
  CrossrefPubMedGoogle Scholar
• 7 Sufka KJ, Loria MJ, Lewellyn K, Zjawiony JK, Ali Z, Abe N, Khan IA. The effect of Salvia divinorum and Mitragyna speciosa extracts, fraction and major constituents on place aversion and place preference in rats. J Ethnopharmacol 2013; 151: 361-364
  PubMedGoogle Scholar
• 8 Matsumoto K, Hatori Y, Murayama T, Tashima K, Wongseripipatana S, Misawa K, Kitajima M, Takayama H, Horie S. Involvement of mu-opioid receptors in antinociception and inhibition of gastrointestinal transit induced by 7-hydroxymitragynine, isolated from Thai herbal medicine Mitragyna speciosa . Eur J Pharmacol 2006; 549: 63-70
  CrossrefPubMedGoogle Scholar
• 9 Garcia Prado E, Garcia Gimenez MD, De la Puerta Vazquez R, Espartero Sanchez JL, Saenz Rodriguez MT. Antiproliferative effects of mitraphylline, a pentacyclic oxindole alkaloid of Uncaria tomentosa on human glioma and neuroblastoma cell lines. Phytomedicine 2007; 14: 280-284
  CrossrefPubMedGoogle Scholar
• 10 Rojas-Duran R, Gonzalez-Aspajo G, Ruiz-Martel C, Bourdy G, Doroteo-Ortega VH, Alban-Castillo J, Robert G, Auberger P, Deharo E. Anti-inflammatory activity of Mitraphylline isolated from Uncaria tomentosa bark. J Ethnopharmacol 2012; 143: 801-804
  CrossrefPubMedGoogle Scholar
• 11 Frackowiak T, Baczek T, Roman K, Zbikowska B, Glensk M, Fecka I, Cisowski W. Binding of an oxindole alkaloid from Uncaria tomentosa to amyloid protein (Abeta1-40). Z Naturforsch C 2006; 61: 821-826
  PubMedGoogle Scholar
• 12 Janchawee B, Keawpradub N, Chittrakarn S, Prasettho S, Wararatananurak P, Sawangjareon K. A high-performance liquid chromatographic method for determination of mitragynine in serum and its application to a pharmacokinetic study in rats. Biomed Chromatogr 2007; 21: 176-183
  CrossrefPubMedGoogle Scholar
• 13 Parthasarathy S, Ramanathan S, Ismail S, Adenan MI, Mansor SM, Murugaiyah V. Determination of mitragynine in plasma with solid-phase extraction and rapid HPLC-UV analysis, and its application to a pharmacokinetic study in rat. Anal Bioanal Chem 2010; 397: 2023-2030
  CrossrefPubMedGoogle Scholar
• 14 Vuppala PK, Jamalapuram S, Furr EB, McCurdy CR, Avery BA. Development and validation of a UPLC-MS/MS method for the determination of 7-hydroxymitragynine, a mu-opioid agonist, in rat plasma and its application to a pharmacokinetic study. Biomed Chromatogr 2013; 27: 1726-1732
  CrossrefPubMedGoogle Scholar
• 15 Wang Q, Rager JD, Weinstein K, Kardos PS, Dobson GL, Li J, Hidalgo IJ. Evaluation of the MDR-MDCK cell line as a permeability screen for the blood-brain barrier. Int J Pharm 2005; 288: 349-359
  CrossrefPubMedGoogle Scholar
• 16 Artursson P, Karlsson J. Correlation between oral drug absorption in humans and apparent drug permeability coefficients in human intestinal epithelial (Caco-2) cells. Biochem Biophys Res Commun 1991; 175: 880-885
  CrossrefPubMedGoogle Scholar
• 17 Mercer SL, Coop A. Opioid analgesics and P-glycoprotein efflux transporters: a potential systems-level contribution to analgesic tolerance. Curr Top Med Chem 2011; 11: 1157-1164
  CrossrefPubMedGoogle Scholar
• 18 Khan IA, Smillie T. Implementing a “quality by design” approach to assure the safety and integrity of botanical dietary supplements. J Nat Prod 2012; 75: 1665-1673
  CrossrefPubMedGoogle Scholar
• 19 Food and Drug Administration, Center for Drug Evaluation and Research. Guidance for industry, waiver of in vivo bioavailability and bioequivalence studies for immediate release solid oral dosage forms containing certain active moieties/active ingredients based on biopharmaceutical classification system. Rockville: FDA; 2000
  Google Scholar
• 20 Malkia A, Murtomaki L, Urtti A, Kontturi K. Drug permeation in biomembranes: in vitro and in silico prediction and influence of physicochemical properties. Eur J Pharm Sci 2004; 23: 13-47
  CrossrefPubMedGoogle Scholar
• 21 Giacomini KM, Huang SM, Tweedie DJ, Benet LZ, Brouwer KL, Chu X, Dahlin A, Evers R, Fischer V, Hillgren KM, Hoffmaster KA, Ishikawa T, Keppler D, Kim RB, Lee CA, Niemi M, Polli JW, Sugiyama Y, Swaan PW, Ware JA, Wright SH, Yee SW, Zamek-Gliszczynski MJ, Zhang L. Membrane transporters in drug development. Nat Rev Drug Discov 2010; 9: 215-236
  CrossrefPubMedGoogle Scholar
• 22 Mittapalli RK, Manda VK, Adkins CE, Geldenhuys WJ, Lockman PR. Exploiting nutrient transporters at the blood-brain barrier to improve brain distribution of small molecules. Ther Deliv 2010; 1: 775-784
  CrossrefPubMedGoogle Scholar
• 23 Madgula VL, Avula B, Pawar RS, Shukla YJ, Khan IA, Walker LA, Khan SI. Characterization of in vitro pharmacokinetic properties of hoodigogenin A from Hoodia gordonii . Planta Med 2010; 76: 62-69
  Article in Thieme ConnectPubMedGoogle Scholar
• 24 Nau R, Sorgel F, Eiffert H. Penetration of drugs through the blood-cerebrospinal fluid/blood-brain barrier for treatment of central nervous system infections. Clin Microbiol Rev 2010; 23: 858-883
  CrossrefPubMedGoogle Scholar
• 25 Liu X, Chen C, Smith BJ. Progress in brain penetration evaluation in drug discovery and development. J Pharmacol Exp Ther 2008; 325: 349-356
  CrossrefPubMedGoogle Scholar
• 26 Kharasch ED, Hoffer C, Whittington D, Sheffels P. Role of P-glycoprotein in the intestinal absorption and clinical effects of morphine. Clin Pharmacol Ther 2003; 74: 543-554
  CrossrefPubMedGoogle Scholar
• 27 Ali Z, Hatejae HD, Khan IA. Isolation, characterization, and NMR spectroscopic data of indole and oxindole alkaloids from Mitragyna speciosa . Tetrahedron Lett 2013; 55: 369-372
  PubMedGoogle Scholar
• 28 Manda VK, Avula B, Ali Z, Wong YH, Smillie TJ, Khan IA, Khan SI. Characterization of in vitro ADME properties of diosgenin and dioscin from Dioscorea villosa . Planta Med 2013; 79: 1421-1428
  Article in Thieme ConnectPubMedGoogle Scholar
• 29 Madgula VL, Avula B, Pawar RS, Shukla YJ, Khan IA, Walker LA, Khan SI. In vitro metabolic stability and intestinal transport of P57AS3 (P57) from Hoodia gordonii and its interaction with drug metabolizing enzymes. Planta Med 2008; 74: 1269-1275
  Article in Thieme ConnectPubMedGoogle Scholar
• 30 Madgula VL, Avula B, Reddy VLN, Khan IA, Khan SI. Transport of decursin and decursinol angelate across Caco-2 and MDR-MDCK cell monolayers: in vitro models for intestinal and blood-brain barrier permeability. Planta Med 2007; 73: 330-335
  Article in Thieme ConnectPubMedGoogle Scholar

• Supplementary Material